Inactivating PAPSS2 mutations in a patient with premature pubarche

  • N Engl J Med. 2009 May 28;360(22):2310-8. doi: 10.1056/NEJMoa0810489.
Cees Noordam  1 ,  Vivek Dhir ,  Joanne C McNelis ,  Florian Schlereth ,  Neil A Hanley ,  Nils Krone ,  Jan A Smeitink ,  Roel Smeets ,  Fred C G J Sweep ,  Hedi L Claahsen-van der Grinten ,  Wiebke Arlt
Affiliations
  • 1. Department of Pediatrics-Metabolic and Endocrine Disorders, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.
Abstract

Dehydroepiandrosterone (DHEA) sulfotransferase, known as SULT2A1, converts the androgen precursor DHEA to its inactive sulfate ester, DHEAS [corrected], thereby preventing the conversion of DHEA to an active androgen. SULT2A1 requires 3'-phosphoadenosine-5'-phosphosulfate (PAPS) for catalytic activity. We have identified compound heterozygous mutations in the gene encoding human PAPS synthase 2 (PAPSS2) in a girl with premature pubarche, hyperandrogenic anovulation, very low DHEAS levels, and increased androgen levels. In vitro coincubation of human SULT2A1 and wild-type or mutant PAPSS2 proteins confirmed the inactivating nature of the mutations. These observations indicate that PAPSS2 deficiency is a monogenic adrenocortical cause of androgen excess.